Differences Between the 23-Valent and 13-Valent Pneumococcal Vaccines
Jun 09, 2022
Source: Cainiu Health
Dr. Guo Xiheng
Introduction
The difference between the 23-valent and 13-valent pneumococcal vaccines lies in their respective recommended age groups and the number of Streptococcus pneumoniae serotypes they protect against. As their names indicate, the key distinction is numerical: “23” and “13” refer to the number of serotypes covered. Specifically, the 23-valent pneumococcal vaccine protects against 23 serotypes of Streptococcus pneumoniae, whereas the 13-valent pneumococcal vaccine protects against 13 serotypes.
Today, with advances in medical technology, an increasing number of preventive vaccines for various diseases have been developed. Infants, in particular, have relatively immature immune systems and lower immunity; therefore, vaccination is essential to boost their antibody production and overall immune capacity. Pneumonia is also common in daily life, yet it can be effectively prevented through vaccination. So, what are the differences between the 23-valent and 13-valent pneumococcal vaccines?
Differences Between the 23-Valent and 13-Valent Pneumococcal Vaccines
The primary differences between the 23-valent and 13-valent pneumococcal vaccines lie in their recommended age groups and the number of Streptococcus pneumoniae serotypes they protect against. As their names indicate, the numbers “13” and “23” refer to the respective numbers of pneumococcal serotypes covered: the 23-valent vaccine protects against 23 serotypes, whereas the 13-valent vaccine covers only 13 serotypes. Consequently, the 23-valent vaccine offers broader protection against a wider range of pneumococcal strains and associated infectious pneumonias.
The appropriate pneumococcal vaccine varies by age group. The 23-valent pneumococcal vaccine is generally recommended for older children and adults, while the 13-valent vaccine is primarily indicated for infants and young children—specifically those aged 6 months to 15 months, and especially for children under 2 years old. This 13-valent vaccine effectively stimulates antibody production in infants and provides long-term protection. For children over 2 years of age, the 23-valent vaccine is typically preferred; however, the 13-valent vaccine remains suitable for this age group as well, particularly due to its favorable safety profile and tolerability in younger children.
In summary, the choice between pneumococcal vaccines can be simply guided by the recipient’s age. We hope this explanation helps clarify your questions.
